PMID- 23197273
OWN - NLM
STAT- MEDLINE
DCOM- 20130624
LR  - 20240426
IS  - 1432-0851 (Electronic)
IS  - 0340-7004 (Print)
IS  - 0340-7004 (Linking)
VI  - 62
IP  - 5
DP  - 2013 May
TI  - Personalized peptide vaccination: a new approach for advanced cancer as 
      therapeutic cancer vaccine.
PG  - 919-29
LID - 10.1007/s00262-012-1379-1 [doi]
AB  - Since both tumor cells and host immune cell repertoires are diverse and 
      heterogeneous, immune responses against tumor-associated antigens should differ 
      substantially among individual cancer patients. Selection of suitable peptide 
      vaccines for individual patients based on the preexisting host immunity before 
      vaccination could induce potent anti-tumor responses that provide clinical 
      benefit to cancer patients. We have developed a novel immunotherapeutic approach 
      of personalized peptide vaccination (PPV) in which a maximum of four human 
      leukocyte antigen (HLA) class IA-matched peptides are selected for vaccination 
      among pooled peptides on the basis of both HLA class IA type and the preexisting 
      host immunity before vaccination. In this review, we discuss our recent results 
      of preclinical and clinical studies of PPV for various types of advanced cancer.
FAU - Noguchi, Masanori
AU  - Noguchi M
AD  - Department of Urology, Kurume University School of Medicine, Kurume, Japan. 
      noguchi@med.kurume-u.ac.jp
FAU - Sasada, Tetsuro
AU  - Sasada T
FAU - Itoh, Kyogo
AU  - Itoh K
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20121130
PL  - Germany
TA  - Cancer Immunol Immunother
JT  - Cancer immunology, immunotherapy : CII
JID - 8605732
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA Antigens)
RN  - 0 (Vaccines, Subunit)
SB  - IM
MH  - Antigens, Neoplasm/immunology
MH  - Cancer Vaccines/*therapeutic use
MH  - Cell Line, Tumor
MH  - Clinical Trials as Topic
MH  - HLA Antigens/metabolism
MH  - Humans
MH  - Immunotherapy/methods
MH  - Medical Oncology/trends
MH  - Neoplasms/*therapy
MH  - Precision Medicine/*methods
MH  - Time Factors
MH  - Vaccines, Subunit/*therapeutic use
PMC - PMC11029009
EDAT- 2012/12/01 06:00
MHDA- 2013/06/26 06:00
PMCR- 2012/11/30
CRDT- 2012/12/01 06:00
PHST- 2012/08/28 00:00 [received]
PHST- 2012/11/16 00:00 [accepted]
PHST- 2012/12/01 06:00 [entrez]
PHST- 2012/12/01 06:00 [pubmed]
PHST- 2013/06/26 06:00 [medline]
PHST- 2012/11/30 00:00 [pmc-release]
AID - 1379 [pii]
AID - 10.1007/s00262-012-1379-1 [doi]
PST - ppublish
SO  - Cancer Immunol Immunother. 2013 May;62(5):919-29. doi: 10.1007/s00262-012-1379-1. 
      Epub 2012 Nov 30.